US4605394A - Methods for the treatment of pathological conditions by removing interferon from the organism - Google Patents

Methods for the treatment of pathological conditions by removing interferon from the organism Download PDF

Info

Publication number
US4605394A
US4605394A US06446680 US44668082A US4605394A US 4605394 A US4605394 A US 4605394A US 06446680 US06446680 US 06446680 US 44668082 A US44668082 A US 44668082A US 4605394 A US4605394 A US 4605394A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
interferon
blood
patient
plasma
apparatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06446680
Inventor
Simon V. Skurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SVS LABORATORIES Inc A Co OF
Original Assignee
Simon V. Skurkovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Abstract

Methods are provided for the treatment of pathological conditions connected with the production of other interferons possessing the damaging action on the cell systems of the organism via the continuous removal of interferon from the organism. This is achieved for example by extracorporeal perfusion of the blood of the patient through the substances absorbing, disintegrating, or inactivating biological activity of interferon. The removal of defective interferon is an effective treatment of cancers and leukemias, and immunodeficiencies.

Description

FIELD OF THE INVENTION

The present invention relates to the treatment of patients having diseases connected with the production of interferons possessing damaging action on the cells. More particularly, the invention provides a method and apparatus for treating such patients by continuously removing interferon from the blood of a patient being treated.

DESCRIPTION OF THE PRIOR ART

This is a continuation-in-part of U.S. Ser. No. 247,205 filed Mar. 24, 1981, now U.S. Pat. No. 4,362,155 granted Dec. 7, 1982.

In 1975, interferon was discovered in the blood of patients with autoimmune diseases and allergy, and preliminary positive results were obtained in treatment of autoimmune and diseases with anti-interferon immunoglobulin (Annals of Allergy, 35:356, December, 1975).

In 1980 and 1982 it was reported that the basis for the development of certain diseases (immune deficiencies, immune suppression in cancer, and others) can be the disturbances of interferon synthesis with the production of defective types of interferon and IFNs possessing damaging action on cells of the organism (Interferon Scientific Memoranda, October 1980, September 1982).

An article entitled "Preparation of Monospecific Immunoglobulin Against Human Leukocytic Interferon" was published in the April 1979, Bulletin of Experimental Biology and Medicine. This articles was primarily directed to the preparation of anti-interferon immunoglobulin for its further use as a substance for the treatment of various allergic and autoimmune diseases.

U.S. Pat. No. 4,172,071, the contents of which are herein incorporated by reference, describes a process for the purification of preparations having an interferon type activity. The process described in this patent involves contacting a solution containing products with interferon type activity with an absorbent that permits the interferon to be retained in a selective manner. The interferon is then separated from the absorbent in a subsequent process.

U.S. Pat. No. 4,168,261, entitled "Method For The Purification of Interferon Using Porous Glass Beads", the contents of which are herein incorporated by reference, describes the purification of an aqueous interferon solution by subjecting the solution to chromatography on porous glass beads. The interferon is subsequently eluted from the beads at an acidic pH. Neither of the references is directed to the removal of interferon from blood, plasma, or plasma with leukocytes. Also, neither of the references is directed to the removal of interferon for the purposes of treating diseases related to hyperproduction of interferon or production of interferon possessing damaging action on the cells.

SUMMARY OF THE INVENTION

The present invention provides for methods of treatment of diseases and syndromes connected with hyperproduction of different types of interferon (IFN), and in particular production of inteferons which disinlegrate immune regulation and have a damaging action on the cells of the organism. These methods include the use of different agents binding, disintegrating, or blocking biological activity of selected interferons and comprise, e.g., antibodies, enzymes, and or other substances. These agents can be administered into the organism, or used in the apparatus for extracorporeal perfusion where the blood containing IFN is passed through these substances which are immobilized, thus clearing the blood from interferon.

These methods can be used for the treatment of immune deficiencies, negative features of aging immuno suppression in cancers and leukemias and other conditions connected with damaging action of IFNs. It is preferable to administer normal IFNs after the removal of IFNs which have a damaging action on cells.

The invention, and its objects and advantages, will become more apparent in the detailed description of the preferred embodiments hereinafter presented.

BRIEF DESCRIPTION OF THE DRAWINGS

In the detailed description of the preferred embodiments of the invention hereinafter presented, reference is made to the accompanying drawings, in which:

FIG. 1 is a schematic illustration of one embodiment apparatus provided by the present invention; and

FIG. 2 is a schematic block diagram of another embodiment of the present invention.

PREFERRED EMBODIMENTS OF THE INVENTION

The present invention provides for methods of treatment of diseases and syndromes connected with production of interferons which disintegrate immune regulations and possess damaging action on the cells of the organism of a patient. Thus, antibodies, enzymes or similarly reacting agents are used for binding, disintegrating or blocking the biological activity of these interferons. The invention preferably uses an apparatus for extracorporeal perfusion where the blood containing interferon is passed through an external reaction chamber containing the above agents and thus the interferon is cleared from the blood. Treatment may also be achieved by the administration of the agents into the organism of the patient to neutralize or remove the damaging effect of the interferon.

The present invention provides for methods of treatment of, immune deficiencies, negative features of aging immuno suppression in cancers and leukemias, and other conditions connected with damaging action of IFN.

The invention utilizes apparatus for removing from or disintegrating, or blocking biological activity of interferon in the organism, and for returning blood having a reduced amount or free from interferon to the patient. Normal interferon may be introduced to the patient after the completion of the clearance process. Hereinafter, the terminology "clearance from interferon" will be used to describe blood that has either a reduced level of interferon or is completely free from interferon by absorption, disintegration, inactivation or suppression of the biological activity of interferon. The method is achieved by apparatus preferably in a closed system in which all of the parts are in fluid communication. During the treatment of a patient, the process of clearance from interferon from the blood is continuous. With this embodiment, the apparatus clears interferon from the whole blood of the patient.

In another embodiment of the invention, a method and apparatus are provided in which interferon is cleared from plasma. Alternatively, the interferon is cleared from plasma containing leukocytes. In either of these cases, it is necessary to pass the whole blood through a blood separator before clearance. Such separator can be a filter or a plasma/cell separator of the type manufactured by American Instrument Co. of Silver Spring, Md. With the embodiment, blood from the patient is first pumped to the separator. The separator separates the blood into plasma (or plasma with leukocytes) and blood cells. Then plasma, or plasma with leukocytes, is pumped from the separator to the clearance system. After clearance of interferon, the plasma or plasma with leukocytes, is rejoined with the blood cells or formed elements of the blood and returned to the patient.

Suitable techniques for purifying interferon are described in the aforementioned U.S. Pat. Nos. 4,168,261 and 4,172,071. These techniques are also usable with the present invention for removing interferon. It should be appreciated that the techniques in these references will require minor modifications when used in the present invention.

For the clearance from interferon the present invention uses anti-interferon antibodies, albumen, and other substances capable of absorbing, disintegrating, inactivating or suppressing the biological activity of interferon. A suitable solid support for these substances may be the Sepharose as described in U.S. Pat. No. 4,172,071.

Blood cleared from interferons which have a damaging action on cells is returned to the patient. It is expedient to administer normal interferons after the removal of abnormal interferons described above.

The following description will be directed in particular to elements forming part of, or cooperating more directly with, the present invention. Elements not specifically shown or described herein are understood to be selectable from those known in the art.

Referring now to the drawings, and to FIG. 1 in particular, one embodiment of an apparatus for treatment of blood to clear interferon is illustrated. The apparatus, which is generally designated 10, comprises an inlet tube 12, means 14 for clearing interferon from blood, and an outlet tube 16. The inlet tube 12 has an inlet end 18 connected to a cannula (not shown) inserted into an artery or blood vessel 20 of a patient. The outlet end 22 of the inlet tube 12 is connected to the inlet 24 of a housing 26 containing a plurality of porous glass beads 28, such as those described in U.S. Pat. No. 4,168,261. The outlet 30 of the housing 26 is connected to an end 32 of the outlet tube 16. The other (outlet) end 34 of tube 16 is connected to a cannula (not shown) inserted into a vein 36 of the patient. Preferably, a pump 36 is included in the apparatus 10. The inlet tube 12 provides means for removing whole blood from a patient, and the outlet tube 16 provides means for returning the blood to the patient. As clearly illustrated in FIG. 1, the tubes 12 and 16 and the means 14 are in continuous fluid communication with each other.

In operation, the cannula connected to the inlet 18 is inserted into the blood vessel of the patient, and the cannula connected to the outlet 34 is inserted into a vein. When a pump is used, the pump is then actuated to pump blood from the patient through the housing 26 so that the beads 28 can remove interferon from the blood. Preferably, all of the interferon is removed from the blood. Blood free from interferon is then returned through the outlet tube 16 into the vein of the patient.

The method used with this embodiment of the invention provides a continuous process for treatment of conditions connected with the damaging action of IFN. The process involves removing blood from a patient, passing the removed blood through means for clearance of the blood from IFN, and returning the blood, which is free from interferon, to the patient.

Referring now to FIG. 2, another embodiment of an apparatus according to the present invention, generally designated 50, is illustrated. The apparatus 50 includes an inlet tube, generally designated 52, and an outlet tube, generally designated 54. The outlet tube 52 is similar to the inlet tube 12, and the outlet tube 54 is similar to the outlet tube 16 of the embodiment illustrated in FIG. 1. A pump 56 is provided to pump blood from the patient into a separator 58. A suitable separator is a plasma filter of the type described in British Pat. No. 1,562,546. Other suitable methods of plasmapheresis, such as centrifugation, also are usable to separate plasma or plasma with leukocytes from the whole blood. The plasma, or plasma with leukocytes, is fed from the separator 58 to a sorbent containing device 60 charged with the aforementioned anti-interferon antibodies. Such device can be the means 14 for removing interferon described in connection with FIG. 1, in general, a device using a process of the type described in U.S. Pat. No. 4,172,071, or any other suitable method using a capacious sorbent for interferon carried by a solid support. The plasma, or plasma with leukocytes, after passing through sorbent within the device 60, rejoins the formed elements of blood removed from the whole blood by the separator 58. A combiner 62 is illustrated for providing the mixing function. Such combiner need be no more complex than a mixing valve having one inlet 64 connected to the separator 58 and a second inlet 66 connected to the device 60. The outlet 68 of the valve is connected to the outlet tube 54. A device 61 for adding heparin to the plasma, or plasma with leukocytes, is positionable between the separator 58 and the device 60. Sections of tubing T interconnect the pump 56, the separator 58, the device 60, the device 61, and the combiner 64, as illustrated in FIG. 2. Thus, the various components of the apparatus 50 are in fluid communication with each other.

The method of clearing blood for treating diseases and conditions connected with damaging action of IFN utilizing the apparatus of FIG. 2 involves the connecting of the inlet and outlet tubes to blood vessel and a vein, respectively, of a patient to be treated; pumping the whole blood of the patient to a separator; separating plasma, or plasma with leukocytes, from blood cells within the separator; passing the plasma, or plasma with leukocytes, through a device for clearing interferon; combining the plasma, or plasma with leukocytes, after clearance of interferon, with the previously removed blood cells; and returning the combined blood to the patient.

In a modification of this embodiment, the separator device separates the blood into plasma (or plasma with leukocytes), and other blood cells. The plasma (or plasma with leukocytes) is processed as previously described.

In another modification, the device 60 utilizes a combined sorbent having a first component for absorbing interferon from the plasma or plasma with leukocytes and a second component that selectively absorbs blocking antibodies in cases of cancers and leukemias, from the plasma or plasma with leukocytes being treated. The particular component is a function of the disease or condition being treated. By utilizing a combined sorbent, the effectiveness of the invention is enhanced.

SPECIFIC EXAMPLES

The present invention includes the following embodiments:

A.

Diseases are treated by the steps of selectively removing blood from the patient, processing the blood of the patient with the means to clear it from interferon, and returning the blood to the patient, while keeping the blood flow path in continuous fluid communication.

B.

The method of treatment of diseases is also carried out by including the step of blocking biological activity of interferon with an interferon clearing agent.

C.

Diseases are also treated by including the steps of separating plasma from the blood residue and processing only the plasma to clear it of interferon, combining the so processed plasma with the blood residue, and returning the combined blood to the patient.

D.

The method of treatment of diseases also includes the step of separating plasma with leukocytes from whole blood, and processing plasma with leukocytes to clear it of interferon, combining the so processed plasma with leukocytes with the blood residue, and returning the combined blood to the patient.

E.

Also included is the step of administering normal interferon after completion of the clearance of interferon process and returning blood to the patient.

F.

The treatment of the present invention includes the step of administering an interferon clearing agent to the organism of the patient to clear interferon from the bloodstream.

G.

Also included is the step of removing blocking antibodies from the blood of cancer patients.

Those novel features believed descriptive of the spirit and nature of the invention are defined with particularity in the claims.

Claims (2)

We claim:
1. In a method of treating diseases comprising the step of selectively clearing the blood of a patient from interferon using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing interferon from the whole blood, and an outlet tube, said method comprising:
connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient;
removing blood from the blood vessel of the patient;
passing the removed blood through the absorbing means for absorbing interferon to thereby reduce the amount of interferon in the blood; and
returning the blood to the vein of the patient,
the improvement comprising:
administering normal interferon after completion of the clearance of interferon process and returning the blood containing normal interferon to the patient.
2. In a method of treating diseases comprising the step of selectively clearing the blood of a patient from interferon using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing interferon from the whole blood, and an outlet tube, said method comprising:
connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient;
removing blood from the blood vessel of the patient;
separating the removed blood into blood cells and plasma:
passing the plasma through the absorbing means for absorbing interferon to thereby reduce the level of interferon within the plasma;
combining the plasma having a reduced level of interferon with the blood cells previously removed from the blood; and
returning the combined blood cells and plasma to the vein of the patient;
the improvement comprising:
administering normal interferon after completion of the clearance of interferon process and returning the blood containing normal interferon to the patient.
US06446680 1982-12-03 1982-12-03 Methods for the treatment of pathological conditions by removing interferon from the organism Expired - Fee Related US4605394A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06446680 US4605394A (en) 1982-12-03 1982-12-03 Methods for the treatment of pathological conditions by removing interferon from the organism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06446680 US4605394A (en) 1982-12-03 1982-12-03 Methods for the treatment of pathological conditions by removing interferon from the organism
US06843528 US4824432A (en) 1981-03-24 1986-03-25 Method for treating AIDS and other immune deficiencies and immune disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06247205 Continuation-In-Part US4362155A (en) 1981-03-24 1981-03-24 Method and apparatus for the treatment of autoimmune and allergic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US06843528 Continuation-In-Part US4824432A (en) 1981-03-24 1986-03-25 Method for treating AIDS and other immune deficiencies and immune disorders

Publications (1)

Publication Number Publication Date
US4605394A true US4605394A (en) 1986-08-12

Family

ID=23773473

Family Applications (1)

Application Number Title Priority Date Filing Date
US06446680 Expired - Fee Related US4605394A (en) 1982-12-03 1982-12-03 Methods for the treatment of pathological conditions by removing interferon from the organism

Country Status (1)

Country Link
US (1) US4605394A (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
US4820261A (en) * 1987-02-21 1989-04-11 Bissendorf Peptide Gmbh Device for the removal of therapeutic substances locally applied for use against solid tumors
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US5078673A (en) * 1988-11-14 1992-01-07 Neorx Corporation Selective removal of radiolabeled antibodies
US5144013A (en) * 1986-09-24 1992-09-01 Ube Industries, Ltd. Body fluid purifying material and method for purifying body fluid by use thereof
US5171837A (en) * 1989-02-08 1992-12-15 Kuraray Co., Ltd. Peptide capable of binding interleukin 6 and an adsorbent comprising the peptide immobilized on a carrier
US5279540A (en) * 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US6033561A (en) * 1993-02-18 2000-03-07 Baxter International Inc. Apheresis system incorporating alternative site for anticoagulant addition
US20020114784A1 (en) * 1999-01-28 2002-08-22 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20020119147A1 (en) * 1999-11-20 2002-08-29 Cytologic, Llc Apparatus for enhancing immune responses in mammals
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20030051263A1 (en) * 1997-12-23 2003-03-13 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US6539252B1 (en) 1996-08-30 2003-03-25 Phillip F. Burris Method and apparatus for the treatment of blood borne pathogens such as immunodeficiency virus
US20030159161A1 (en) * 1998-03-20 2003-08-21 Graham Michael Wayne Synthetic genes and genetic constructs comprising same I
US20040152117A1 (en) * 2001-01-31 2004-08-05 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20040198690A1 (en) * 1999-04-21 2004-10-07 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20040237145A1 (en) * 1998-03-20 2004-11-25 Graham Michael Wayne Control of gene expression
US6863890B1 (en) 1993-02-26 2005-03-08 Advanced Biotherapy, Inc. Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
US20050244371A1 (en) * 1998-05-22 2005-11-03 Biopheresis Technologies, Llc Method and system to remove cytokine inhibitor in patients
US20050265996A1 (en) * 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20070219151A1 (en) * 1999-04-21 2007-09-20 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US20080160030A1 (en) * 2005-02-10 2008-07-03 Banchereau Jacques F Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use
US20080262408A1 (en) * 2005-03-11 2008-10-23 Martin Krauss Multi-Constituent Packaging with Applicator
US20090155286A1 (en) * 2004-10-07 2009-06-18 Michel Gilliet Type I interferon blocking agents for prevention and treatment of psoriasis
US20090214565A1 (en) * 2005-02-10 2009-08-27 Jacques Banchereau Anti-Interferon Alpha Monoclonal Antibodies and Methods For Use
US20100285044A1 (en) * 1998-05-22 2010-11-11 Lentz M Rigdon Method and compositions for treatment of cancers
US20110213125A1 (en) * 2008-05-07 2011-09-01 Novo Nordisk A/S Humanized Antibodies Against Human Interferon-Alpha
US8183217B2 (en) 1999-08-13 2012-05-22 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US9227005B2 (en) 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
US20160354534A1 (en) * 2013-12-17 2016-12-08 University Of Limerick Apparatus for the extracorporeal treatment of blood
US9694128B1 (en) * 2010-02-24 2017-07-04 Brian LeBerthon Device and method for administering an anti-cancer substance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168261A (en) * 1976-05-28 1979-09-18 Stichting Rega V.Z.W. Method for the purification of interferon using porous glass beads
US4172071A (en) * 1976-05-21 1979-10-23 Agence Nationale De Valorisation De La Recherche (Anvar) Chromophore blue adsorbent method for the purification of preparations having an interferon type activity
US4223672A (en) * 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4273703A (en) * 1977-11-01 1981-06-16 Ess-Food Eksport-Svineslagteriernes Salgsforening Interferon product and process for its preparation
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172071A (en) * 1976-05-21 1979-10-23 Agence Nationale De Valorisation De La Recherche (Anvar) Chromophore blue adsorbent method for the purification of preparations having an interferon type activity
US4168261A (en) * 1976-05-28 1979-09-18 Stichting Rega V.Z.W. Method for the purification of interferon using porous glass beads
US4273703A (en) * 1977-11-01 1981-06-16 Ess-Food Eksport-Svineslagteriernes Salgsforening Interferon product and process for its preparation
US4223672A (en) * 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Annals of Allergy, "The Probable Role of Interferon in Allergy"; vol. 35, Dec. 1975; S. V. Skurkovich et al.
Annals of Allergy, The Probable Role of Interferon in Allergy ; vol. 35, Dec. 1975; S. V. Skurkovich et al. *
Interferon Scientific Memoranda, "Disturbances of Interferon Synthesis"; Sep. 1982, S. Skurkovich et al.
Interferon Scientific Memoranda, "Interferon Disease, Interferon Syndrome"; Oct. 1980; S. V. Skurkovich.
Interferon Scientific Memoranda, Disturbances of Interferon Synthesis ; Sep. 1982, S. Skurkovich et al. *
Interferon Scientific Memoranda, Interferon Disease, Interferon Syndrome ; Oct. 1980; S. V. Skurkovich. *
Nature, "Immunosuppressive Effect of an Anti-Interferon Serum"; Feb. 22, 1974.
Nature, Immunosuppressive Effect of an Anti Interferon Serum ; Feb. 22, 1974. *

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
US5144013A (en) * 1986-09-24 1992-09-01 Ube Industries, Ltd. Body fluid purifying material and method for purifying body fluid by use thereof
US4820261A (en) * 1987-02-21 1989-04-11 Bissendorf Peptide Gmbh Device for the removal of therapeutic substances locally applied for use against solid tumors
EP0344201B1 (en) * 1987-02-21 1991-07-31 Pharma Biotechnologie Hannover Gmbh Device for the removal of active substances locally applied against solid tumors
US5209717A (en) * 1987-02-21 1993-05-11 Pharma Biotechnologie Hannover Gmbh Method and device for local application and removal of active substances against solid tumors
US5078673A (en) * 1988-11-14 1992-01-07 Neorx Corporation Selective removal of radiolabeled antibodies
US5171837A (en) * 1989-02-08 1992-12-15 Kuraray Co., Ltd. Peptide capable of binding interleukin 6 and an adsorbent comprising the peptide immobilized on a carrier
US5279540A (en) * 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
US6033561A (en) * 1993-02-18 2000-03-07 Baxter International Inc. Apheresis system incorporating alternative site for anticoagulant addition
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
US6333032B1 (en) 1993-02-26 2001-12-25 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases
US20050175604A1 (en) * 1993-02-26 2005-08-11 Advanced Biotherapy, Inc. Treatment of autoimmune diseases, including AIDS
US6863890B1 (en) 1993-02-26 2005-03-08 Advanced Biotherapy, Inc. Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
US6539252B1 (en) 1996-08-30 2003-03-25 Phillip F. Burris Method and apparatus for the treatment of blood borne pathogens such as immunodeficiency virus
EP1975180A1 (en) 1996-12-23 2008-10-01 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases with antibody anti gamma interferon
US20030051263A1 (en) * 1997-12-23 2003-03-13 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US20030055020A1 (en) * 1997-12-23 2003-03-20 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US8580754B2 (en) 1997-12-23 2013-11-12 Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US7538095B2 (en) 1997-12-23 2009-05-26 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US7560438B2 (en) 1997-12-23 2009-07-14 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US8283329B2 (en) 1997-12-23 2012-10-09 The Carnegie Institution Of Washington Genetic inhibition of double-stranded RNA
US7622633B2 (en) 1997-12-23 2009-11-24 Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US20030056235A1 (en) * 1997-12-23 2003-03-20 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US9102939B2 (en) 1997-12-23 2015-08-11 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US20080050342A1 (en) * 1997-12-23 2008-02-28 Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US20040237145A1 (en) * 1998-03-20 2004-11-25 Graham Michael Wayne Control of gene expression
US9029527B2 (en) 1998-03-20 2015-05-12 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US8067383B2 (en) 1998-03-20 2011-11-29 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs comprising same I
US8053419B2 (en) 1998-03-20 2011-11-08 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US8048670B2 (en) 1998-03-20 2011-11-01 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US7754697B2 (en) 1998-03-20 2010-07-13 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US20040180439A1 (en) * 1998-03-20 2004-09-16 Benitec Australia Limited Synthetic genes and genetic constructs
US8168774B2 (en) 1998-03-20 2012-05-01 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US8431547B2 (en) 1998-03-20 2013-04-30 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US20030159161A1 (en) * 1998-03-20 2003-08-21 Graham Michael Wayne Synthetic genes and genetic constructs comprising same I
US20040266005A1 (en) * 1998-03-20 2004-12-30 Benitec Australia Limited Synthetic genes and genetic constructs
US20060014715A1 (en) * 1998-03-20 2006-01-19 Benitec Australia Limited Control of gene expression
US9963698B2 (en) 1998-03-20 2018-05-08 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US20080057060A1 (en) * 1998-05-22 2008-03-06 Biopheresis Technologies, Llc Method and system to remove cytokine inhibitor in patients
US20050244371A1 (en) * 1998-05-22 2005-11-03 Biopheresis Technologies, Llc Method and system to remove cytokine inhibitor in patients
US20080145333A1 (en) * 1998-05-22 2008-06-19 Biopheresis Technologies, Inc. Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
US8133490B2 (en) 1998-05-22 2012-03-13 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitors in patients
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US20100285044A1 (en) * 1998-05-22 2010-11-11 Lentz M Rigdon Method and compositions for treatment of cancers
US7854717B1 (en) 1998-05-22 2010-12-21 Biopheresis Technologies, Inc. Method and compositions for treatment of cancers
US8148345B2 (en) 1999-01-28 2012-04-03 Georgia Health Sciences University Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20040147475A1 (en) * 1999-01-28 2004-07-29 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20090156520A1 (en) * 1999-01-28 2009-06-18 Med. College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20020114784A1 (en) * 1999-01-28 2002-08-22 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US20090215880A1 (en) * 1999-01-28 2009-08-27 Med. College Of Georgia Research Institute, Inc. Composition and Method for IN VIVO and IN VITRO Attenuation of Gene Expression Using Double Stranded RNA
US20080081792A1 (en) * 1999-04-21 2008-04-03 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20040198690A1 (en) * 1999-04-21 2004-10-07 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US20070219151A1 (en) * 1999-04-21 2007-09-20 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US8334374B2 (en) 1999-08-13 2012-12-18 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US9708621B2 (en) 1999-08-13 2017-07-18 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US8183217B2 (en) 1999-08-13 2012-05-22 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US20110201986A1 (en) * 1999-11-20 2011-08-18 Cytologic, Inc. Method for enhancing immune responses in mammals
US20020119147A1 (en) * 1999-11-20 2002-08-29 Cytologic, Llc Apparatus for enhancing immune responses in mammals
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7544357B2 (en) 2001-01-09 2009-06-09 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20040067232A1 (en) * 2001-01-09 2004-04-08 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20040152117A1 (en) * 2001-01-31 2004-08-05 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US20050265996A1 (en) * 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
US20060182747A1 (en) * 2004-06-15 2006-08-17 Advanced Biotherapy, Inc. Treatment of autism
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20060188505A1 (en) * 2004-06-15 2006-08-24 Advanced Biotherapy, Inc. Treatment of autism
US20090155286A1 (en) * 2004-10-07 2009-06-18 Michel Gilliet Type I interferon blocking agents for prevention and treatment of psoriasis
US20080160030A1 (en) * 2005-02-10 2008-07-03 Banchereau Jacques F Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8333965B2 (en) 2005-02-10 2012-12-18 Baylor Research Institute Anti-inteferon alpha monoclonal antibodies and methods for use
US20090214565A1 (en) * 2005-02-10 2009-08-27 Jacques Banchereau Anti-Interferon Alpha Monoclonal Antibodies and Methods For Use
US8080638B2 (en) 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US20080262408A1 (en) * 2005-03-11 2008-10-23 Martin Krauss Multi-Constituent Packaging with Applicator
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US8501918B2 (en) 2005-09-22 2013-08-06 Cytologic, Inc. Immobilized tumor necrosis factor-α muteins for enhancing immune response in mammals
US20090227750A1 (en) * 2005-09-22 2009-09-10 Mark Douglas Howell Mehod for enhancing immune response in mammals
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US8658771B2 (en) 2008-05-07 2014-02-25 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US8361463B2 (en) 2008-05-07 2013-01-29 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US8163885B2 (en) 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US20110213125A1 (en) * 2008-05-07 2011-09-01 Novo Nordisk A/S Humanized Antibodies Against Human Interferon-Alpha
US9694128B1 (en) * 2010-02-24 2017-07-04 Brian LeBerthon Device and method for administering an anti-cancer substance
US9227005B2 (en) 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
US20160354534A1 (en) * 2013-12-17 2016-12-08 University Of Limerick Apparatus for the extracorporeal treatment of blood

Similar Documents

Publication Publication Date Title
Hakim et al. Complement activation and hypersensitivity reactions to dialysis membranes
Bansal et al. Ex vivo removal of serum IgG in a patient with colon carcinoma. Some biochemical, immunological and histological observations
US5801063A (en) Device and process for the biospecific removal of heparin
US5177194A (en) Process for purifying immune serum globulins
US4648974A (en) Process for the selective extracorporeal separation of blood constituents
Wallace et al. Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis
Langer et al. An enzymatic system for removing heparin in extracorporeal therapy
US4526715A (en) Method of preparing highly purified, stroma-free, non-hepatitic human and animal hemoglobin solutions
US4341764A (en) Method of preparing fibronectin and antihemophilic factor
US4770774A (en) Column for removing β2 -microglobulin
US4684521A (en) Method and system for externally treating the blood
US4172071A (en) Chromophore blue adsorbent method for the purification of preparations having an interferon type activity
US5004548A (en) Method and apparatus for rinsing and priming an exchanger
US6039946A (en) Extracorporeal affinity adsorption devices
US5094960A (en) Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US4440675A (en) Human immune interferon
US3991181A (en) Injectable stroma free hemoglobin solution and its method of manufacture
US6866846B1 (en) Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation
US5618663A (en) Device for producing a supernatant of activated thrombocytes, method for implementing the device and supernatant obtained
US4787883A (en) Extracorporal thermo-therapy device and method for curing diseases
US5215927A (en) Method for immunoselection of cells using avidin and biotin
US4614513A (en) Method and apparatus for treatment to remove immunoreactive substances from blood
US5225353A (en) Method for immunoselection of cells using avidin and biotin
Dall'Amico et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis.
US4428744A (en) Method and system for externally treating the blood

Legal Events

Date Code Title Description
CC Certificate of correction
AS Assignment

Owner name: S.V.S. LABORATORIES, INC., 802 ROLLINS AVE., ROCKV

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SKURKOVICH, SIMON, V.,;REEL/FRAME:004819/0054

Effective date: 19880103

Owner name: S.V.S. LABORATORIES, INC., A COMPANY OF MD,MARYLAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SKURKOVICH, SIMON, V.,;REEL/FRAME:004819/0054

Effective date: 19880103

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 19940817